RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All FDA (CDER) updates
FDA (CDER)
GUIDANCE FINAL
Questions and Answers on Biosimilar Development and the BPCI Act: Guidance for Industry
Published: 10/9/2026Detected: 3/19/2026

Summary preview

Clarifies how FDA expects sponsors to develop, evaluate, and submit biosimilar applications under the BPCI Act, with emphasis on demonstrating biosimilarity/clinical similarity while meeting BLA submission expectations.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
immunology
infectious_disease
oncology
cardiology
neurology
hematology
gastroenterology
respiratory
ophthalmology
pediatrics

Official Source Document
Source Verified

Access the original document directly from FDA CDER.

View Official Document

More from FDA (CDER)

  • E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
  • Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
  • Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
  • Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
  • Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026

Get FDA (CDER) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
rare_diseases
dermatology
psychiatry
manufacturing
quality
clinical
safety
labeling
#biosimilar
#BPCI Act
#BLA
#totality of the evidence
#bioanalytical
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.